# Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

> **NCT03947970** · PHASE1 · COMPLETED · sponsor: **Cara Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Hemodialysis
- Healthy

## Interventions

- **DRUG:** [14C] CR845

## Key facts

- **NCT ID:** NCT03947970
- **Lead sponsor:** Cara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2019-04-06
- **Final completion:** 2019-04-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947970, "Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03947970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*